The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Are 20 human papillomavirus types causing cervical cancer?
Open accessAbstract
In 2012, the International Agency for Research on Cancer concluded that there was consistent and sufficient epidemiological, experimental and mechanistic evidence of carcinogenicity to humans for 12 HPV types (HPV16, HPV18, HPV31, HPV33, HPV35, HPV39, HPV45, HPV51, HPV52, HPV56, HPV58 and HPV59) for cervical cancer. Therefore, these types were considered as 1A carcinogens. They all belong to the family of the α‐Papillomaviridae, in particular to the species α 5 (HPV51), α 6 (HPV56), α 7 (HPV18, HPV39, HPV45, HPV59) and α 9 (HPV16, HPV31, HPV33, HPV35, HPV52, HPV58). Less evidence is available for a thirteenth type (HPV68, α 7), which is classified as a 2A carcinogen (probably carcinogenic). Moreover, seven other phylogenetically related types (HPV26, HPV53, HPV66, HPV67, HPV68, HPV70 and HPV73) were identified as single HPV infections in certain rare cases of cervical cancer and were considered possibly carcinogenic (2B carcinogens). Recently, Halec et al [7] demonstrated that the molecular signature of HPV‐induced carcinogenesis (presence of type‐specific spliced E6*| mRNA; increased expression of p16; and decreased expression of cyclin D1, p53 and Rb) was similar in cervical cancers containing single infections with one of the eight afore‐mentioned 2A or 2B carcinogens to those in cancers with single infections with group 1 carcinogens. Ninety six percent of cervical cancers are attributable to one of the 13 most common HPV types (groups 1 and 2A). Including the additional seven HPV types (group 2B) added 2.6%, to reach a total of 98.7% of all HPV‐positive cervical cancers. From recently updated meta‐analyses, it was shown that HPV68, HPV26, HPV66, HPV67, HPV73 and HPV82 were significantly more common in cancer cases than in women with normal cervical cytology, suggesting that for these HPV types, an upgrading of the carcinogen classification could be considered. However, there is no need to include them in HPV screening tests or vaccines, given their rarity in cervical cancers. Copyright © 2014 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
de Sanjose, S., Quint, W. G., Alemany, L., Geraets, D. T., Klaustermeier, J. E., Lloveras, B., Tous, S., Felix, A., Bravo, L. E., Shin, H.-R., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70230-8 · Cited by 2,728
Worldwide burden of cervical cancer in 2008
Arbyn, M., Castellsagué, X., de Sanjosé, S., Bruni, L., Saraiya, M., Bray, F., & Ferlay, J. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr015 · Cited by 1,130
Self-citationEvidence Regarding Human Papillomavirus Testing in Secondary Prevention of Cervical Cancer
Arbyn, M., Ronco, G., Anttila, A., Meijer, C. J. L. M., Poljak, M., Ogilvie, G., Koliopoulos, G., Naucler, P., Sankaranarayanan, R., & Peto, J. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.06.095 · Cited by 897
Self-citationBosch, F. X., Burchell, A. N., Schiffman, M., Giuliano, A. R., de Sanjose, S., Bruni, L., Tortolero-Luna, G., Kjaer, S. K., & Muñoz, N. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.05.064 · Cited by 842
Kleter, B., van Doorn, L.-J., Schrauwen, L., Molijn, A., Sastrowijoto, S., ter Schegget, J., Lindeman, J., ter Harmsel, B., Burger, M., & Quint, W. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.8.2508-2517.1999 · Cited by 655
The human papillomavirus family and its role in carcinogenesis
Tommasino, M. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.11.002 · Cited by 411
Self-citationA systematic review of the prevalence of mucosal and cutaneous human papillomavirus types
Bzhalava, D., Guan, P., Franceschi, S., Dillner, J., & Clifford, G. (2013) · Virology · doi:10.1016/j.virol.2013.07.015 · Cited by 312
Self-citationSchmitt, M., Depuydt, C., Benoy, I. H., Bogers, J., Antoine, J., Arbyn, M., & Pawlita, M. (2013) · Journal of Clinical Microbiology · doi:10.1128/jcm.00087-13 · Cited by 151
Self-citationA Study of the Impact of Adding HPV Types to Cervical Cancer Screening and Triage Tests
SCHIFFMAN, M. H., Khan, M. J., Solomon, D., Herrero, R., Wacholder, S., Hildesheim, A., Rodríguez, A. C., Bratti, M. C., Wheeler, C. M., Burk, R. D., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji014 · Cited by 144
Human papillomavirus in a necessary cause of invasive cervical cancer worldwide
(1999) · Pure Amsterdam UMC · doi:10.1002/(sici)1096-9896(199909)189:1 · Cited by 140
Halec, G., Alemany, L., Lloveras, B., Schmitt, M., Alejo, M., Bosch, F. X., Tous, S., Klaustermeier, J. E., Guimerà, N., Grabe, N., et al. (2014) · The Journal of Pathology · doi:10.1002/path.4405 · Cited by 139
Biological activity of probable/possible high‐risk human papillomavirus types in cervical cancer
Halec, G., Schmitt, M., Dondog, B., Sharkhuu, E., Wentzensen, N., Gheit, T., Tommasino, M., Kommoss, F., Bosch, F. X., Franceschi, S., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27605 · Cited by 137
Self-citationHiller, T., Poppelreuther, S., Stubenrauch, F., & Iftner, T. (2006) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-05-0778 · Cited by 96
Eklund, C., Forslund, O., Wallin, K., & Dillner, J. (2013) · Journal of Clinical Microbiology · doi:10.1128/jcm.02453-13 · Cited by 91
Self-citationChanges in type‐specific human papillomavirus load predict progression to cervical cancer
Depuydt, C., Criel, A. M., Benoy, I. H., et al. (2012) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2012.01631.x · Cited by 68
Self-citationPrevalence and viral load of 51 genital human papillomavirus types and three subtypes
Schmitt, M., Depuydt, C., Benoy, I. H., Bogers, J., Antoine, J., Arbyn, M., Pawlita, M., & on behalf of the VALGENT Study Group (2012) · International Journal of Cancer · doi:10.1002/ijc.27891 · Cited by 64
Self-citationArbyn, M., Benoy, I. H., Simoens, C., Bogers, J., Beutels, P., & Depuydt, C. (2009) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-08-0510 · Cited by 63
Self-citationSmelov, V., Elfström, K. M., Johansson, A. L. V., Eklund, C., Nauclér, P., Arnheim‐Dahlström, L., & Dillner, J. (2014) · International Journal of Cancer · doi:10.1002/ijc.29085 · Cited by 61
Self-citationMansour, M., Touka, M., Hasan, U. A., Bellopede, A., Smet, A., Accardi, R., Gabet, A., Sylla, B. S., & Tommasino, M. (2007) · Virology · doi:10.1016/j.virol.2007.05.005 · Cited by 18
Self-citationTjalma, W. A. A., & Depuydt, C. (2014) · PubMed · Cited by 10
Self-citation
Cited by
Arbyn, M., Xu, L., Simoens, C., & Martin-Hirsch, P. P. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009069.pub3 · Cited by 621
Self-citation2020 list of human papillomavirus assays suitable for primary cervical cancer screening
Arbyn, M., Simon, M., Peeters, E., Xu, L., Meijer, C. J. L. M., Berkhof, J., Cuschieri, K., Bonde, J., Ostrbenk Vanlencak, A., Zhao, F.-H., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.04.031 · Cited by 284
Self-citationWhich high-risk HPV assays fulfil criteria for use in primary cervical cancer screening?
Arbyn, M., Snijders, P. J. F., Meijer, C. J. L. M., Berkhof, J., Cuschieri, K., Kocjan, B. J., & Poljak, M. (2015) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2015.04.015 · Cited by 275
Self-citationVALGENT: a protocol for clinical validation of human papillomavirus assays
Arbyn, M., Depuydt, C., Benoy, I., Bogers, J., Cuschieri, K., Schmitt, M., Pawlita, M., Geraets, D., Heard, I., Gheit, T., et al. (2016) · Journal of Clinical Virology · doi:10.1016/j.jcv.2015.09.014 · Cited by 157
Self-citationAssessment of the Roche Linear Array HPV Genotyping Test within the VALGENT framework
Xu, L., Oštrbenk, A., Poljak, M., & Arbyn, M. (2018) · Journal of Clinical Virology · doi:10.1016/j.jcv.2017.12.001 · Cited by 45
Self-citation
Metadata
- Authors
- Arbyn, M., Tommasino, M., Depuydt, C., & Dillner, J.
- Venue
- The Journal of Pathology
- Publisher
- Wiley
- Published
- 2014-11-11
- Volume
- 234
- Issue
- 4
- Pages
- 431-435
- ISSN
- 0022-3417 (ISSN-L)
- 1096-9896
- OpenAlex
- W2100775423
- Cited by
- 264
- References
- 20
- FWCI
- 12.81
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
